

22 November 2010 EMA/CVMP/649372/2010 Veterinary Medicines and Product Data Management

# Committee for Medicinal Products for Veterinary Use

Monthly report of application procedures, guidelines and related documents November 2010

The CVMP monthly report includes statistical data for the current and previous two years on scientific advice, initial evaluations, variations, line extensions, renewals, MRLs initial evaluations and MRLs extensions/modifications and arbitration and referral procedures.

In addition, the report includes a summary table of the opinions issued by the CVMP in the current year and a list of adopted guidelines and other public documents.

# Applications for medicinal products for veterinary use and maximum residue limits (MRLs)

Scientific advice requests								
	95-07 2008 2009 2010 Total							
Submitted 58 5 11 20 94								

Initial evaluation								
	95-07	2008	2009	2010	Total			
Full	97	13	14	15	139			
(Submitted)								
Abridged/	7	3	1	2	13			
generics								
(Submitted)								
Withdrawals	11	1	0	1	13			
Positive	78	13	13	9	113			
opinions								
Negative	1	0	0	0	1			
opinions								

Marketing authorisations							
	95-07	2008	2009	2010	Total		
Granted	75	13	12	8	108		
Withdrawals	1 1 0 4 6						
Not renewed	2	0	0	0	2		

Extensions - Annex II Applications									
	95-07 2008 2009 2010 Total								
Submitted	56	4	12	3	73				
Withdrawals	1	1	1	1	4				
Positive	33	7	7	8	55				
opinions									
Negative	0	0	0	0	0				
opinions									



Variations – applications submitted									
	95-07	95-07 2008 2009 2010 Total							
Type IA	291	23	32	71	539				
Type IB	291	25	41	56	539				
Type II	158	52	40	25	275				
Transfers	9	2	3	6	20				

Renewals							
	95-07	2008	2009	2010	Total		
Submitted	43	7	18	6	74		
Positive	40	8	17	8	73		
opinions							
Negative	0	0	0	0	0		
opinions							

Arbitrations and Community referrals								
	95-07 2008 2009 2010 Total							
Referrals submitted	27 11 9 11 57							
Opinions 14 6 14 4 43 reached								

Establishment of MRLs for new substances									
	95-07 2008 2009 2010 Total								
Submitted	65	1	4	3	73				
Withdrawals	5	0	0	0	5				
Positive	52	2	2	2	58				
opinions <sup>1</sup>									
Negative	6	1	0	0	7				
opinions <sup>2</sup>									

Extensions / modifications/extrapolations of MRLs								
	95-07	2008	2009	2010	Total			
Submitted	96	2	2	9	109			
Withdrawals	4	0	0	0	4			
Positive	111	2	3	2	118			
opinions <sup>3</sup>								
Negative	6	0	0	0	6			
opinions <sup>4</sup>								
Extrapolations	45	5	0	0	50			

<sup>&</sup>lt;sup>1</sup> Including opinions recommending definitive MRLs for substances with previously provisional maximum residue limits <sup>2</sup> Including one opinion concluding that final MRL could not be established for a substance with provisional maximum residue limits previously established

# CVMP opinions in 2010 on medicinal products for veterinary use

Positive opinions

Drc	oduct	•	Marketing	The	erapeutic area	ΕM	A/CVMP	Fu	ropean Commission
110	duct		authorisation	•	Target species				
•	Invented name		holder			•	Validation Opinion	•	Opinion received  Date of decision
•	INN			•	Summary of indication	•	Active time	•	Notification
					malcation		Clock stop		Official Journal
•	Bovilis BTV 8	•	Intervet	•	cattle, sheep	•	22/04/2008	•	17/06/2010
	Bovilla BTV 0		International	•	inactivated	•	16/06/2010		06/09/2010
			BV	-	vaccine against	•	197		00/07/2010
					Bluetongue virus	•	589		
					serotype 8				
•	BTVPUR AlSap 2-4	•	Merial S.A.S.	•	sheep	•	18/12/2007	•	15/07/2010
				•	inactivated	•	14/07/2010	•	05/11/2010
					vaccine against	•	209		
					Bluetongue virus	•	728		
					serotypes 2 and				
					4				
•	Veraflox	•	Bayer Animal	•	dogs, cats	•	19/05/2009	•	15/07/2010
			Health GmbH	•	infections caused	•	14/07/2010		
					by certain	•	202		
					specified and	•	218		
					susceptible				
	BUINIOENO				pathogens .		1/10/1000		45/07/0040
•	RHINISENG	•	Laboratorios	•	pigs	•	16/06/2009	•	15/07/2010
			Hipra S.A.	•	inactivated	•	14/07/2010	•	16/09/2010
					vaccine to	•	209 181		
					prevent non- progressive	•	101		
					atropic rhinitis in				
					pigs				
•	COXEVAC	•	Ceva Sante	•	cattle, goats	•	17/12/2008	•	15/07/2010
			Animale	•	inactivated	•	14/07/2010	•	30/09/2010
					coxiella burnetti	•	203		
					vaccine	•	370		
•	Meloxoral	•	LeVet B.V.	•	dogs, cats	•	17/06/2008	•	16/09/2010
•	Meloxicam			•	alleviation of	•	14/09/2010	•	19/11/2010
					inflammation and	•	210		
<u> </u>					pain	•	609		
•	BTVPUR AISAP 1	•	Merial	•	sheep, cattle	•	10/12/2009	•	14/10/2010
				•	inactivated	•	13/10/2010		
					vaccine against	•	180		
					Bluetongue virus	•	126		
<u> </u>	DT/DUD 41015 1				serotypes 1		40/40/0000		4.440.40010
•	BTVPUR AISAP 1-	•	Merial	•	sheep, cattle	•	10/12/2009	•	14/10/2010
	8			•	inactivated	•	13/10/2010		
					vaccine against	•	180		
		<u> </u>			Bluetongue virus	•	126		

					serotypes 1 and				
					8				
•	Hiprabovis IBR	•	Laboratorios	•	Cattle	•	17/03/2009	•	11/11/2010
	Marker Live		Hipra S.A.	•	A live vaccine	•	10/11/2010		
					against infectious	•	204		
					bovine	•	398		
					rhinotracheitis				
					(IBR)				

# CVMP opinions in 2010 on establishment of MRLs for new substances

Positive opinions

<ul><li>Substance</li><li>INN</li><li>Derquantel</li></ul>	<ul><li>Therapeutic area</li><li>Target species</li><li>Ovine</li></ul>	EMA/CVMP  Validation Opinion Active time Clock stop 18/06/2009	<ul> <li>European Commission</li> <li>Opinion received</li> <li>Date of regulation</li> <li>Official Journal</li> <li>07/06/2010</li> </ul>
		<ul><li>19/05/2010</li><li>119</li><li>206</li></ul>	
Monepantel     (extension of provisional MRLs)	Caprine	<ul><li>N/a</li><li>15/09/2010</li><li>N/a</li><li>N/a</li></ul>	• 29/09/2010
Isoeugenol	Fin fish	<ul><li>17/09/2009</li><li>15/09/2010</li><li>209</li><li>218</li></ul>	• 29/09/2010
• Closantel (Procedure under Article 9(1b) of Regulation 470/2009)	Bovine and ovine milk	<ul><li>N/a</li><li>15/09/2010</li><li>97</li><li>0</li></ul>	• 29/09/2010
• Triclabendazole  (Procedure under Article 9(1b) of Regulation 470/2009)	Milk of all ruminants	<ul><li>N/a</li><li>10/11/2010</li><li>152</li><li>0</li></ul>	• 16/11/2010

# **Arbitrations and Community referrals in 2010**

Type of referral	Date of clock start	Product name
	CVMP opinion	• INN
Referral under Art. 35	• 11/02/2009	All strengths of water soluble powders and
of Directive	• 10/02/2010	oral solutions containing doxycycline hyclate
2001/82/EC		Doxycycline hyclate

Type of referral  Referral under Art. 35 of Directive 2001/82/EC	<ul> <li>Date of clock start</li> <li>CVMP opinion</li> <li>16/04/2009</li> <li>10/02/2010</li> </ul>	<ul> <li>Product name</li> <li>INN</li> <li>Veterinary medicinal formulations containing colistin at 2 MIU/ml and intended for administration in drinking water to any food producing species</li> <li>Colistin sulfate</li> </ul>
Referral under Art. 35 of Directive 2001/82/EC	<ul><li>13/05/2009</li><li>10/03/2010</li><li>(after re-examination)</li></ul>	<ul> <li>Veterinary medicinal products containing quinolones or fluoroquinolones for all food- producing species</li> <li>Quinolones / fluoroquinolones</li> </ul>
Referral under Art. 33(4) of Directive 2001/82/EC Referral under Art. 6(12) of Regulation	<ul> <li>12/11/2008</li> <li>11/11/2009     (after re-examination)</li> <li>14/10/2009</li> <li>19/05/2010</li> </ul>	<ul> <li>Tildren 500 mg</li> <li>Tiludronic acid (as disodium salt)</li> <li>Porcilis PRRS</li> </ul>
(EC) No 1084/2003 Referral under Art. 6(12) of Regulation (EC) No 1084/2003	<ul><li>14/10/2009</li><li>19/05/2010</li></ul>	<ul> <li>Live attenuated PRRS virus strain DV</li> <li>Porcilis M Hyo</li> <li>Inactivated whole cell concentrate of Mycoplasma hyopneumoniae strain 11</li> </ul>
Referral under Art. 34 of Directive 2001/82/EC	• 11/11/2009	<ul> <li>Fortekor vet and associated names</li> <li>Benazepril hydrochloride</li> </ul>
Referral under Art. 34 of Directive 2001/82/EC	<ul><li>15/10/2008</li><li>10/03/2010</li></ul>	<ul><li>Tiamutin premix</li><li>Tiamulin fumarate</li></ul>
Referral under Art. 34 of Directive 2001/82/EC	• 14/04/2010	<ul> <li>Synulox Lactating Cow and associated names</li> <li>Amoxicillin, clavulanic acid, prednisolone</li> </ul>
Procedure under Art. 78 of Directive 2001/82/EC	<ul><li>19/05/2010</li><li>14/07/2010</li></ul>	<ul> <li>Pregsure BVD and associated names</li> <li>Inactivated Bovine Viral Diarrhoea (BVD) type 1 virus</li> </ul>
Procedure under Art. 30(3) of Regulation 726/2004	<ul><li>19/05/2010</li><li>15/09/2010</li></ul>	<ul> <li>Retrovirus RD114 in relation to live attenuated vaccines for use in dogs and cats</li> <li>N/a</li> </ul>
Procedure under Art. 45 of Regulation (EC) No 726/2004	<ul><li>16/06/2010</li><li>14/07/2010</li></ul>	<ul> <li>Suvaxyn PCV</li> <li>Inactivated recombinant Porcine Circovirus type 1 expressing the Porcine Circovirus type 2 ORF2 protein</li> </ul>
Referral under Art. 33(4) of Directive 2001/82/EC	• 14/07/2010	<ul> <li>Combimox Lactating Cow</li> <li>Amoxicillin, clavulanic acid, prednisolone</li> </ul>

Type of referral	Date of clock start	Product name
	CVMP opinion	• INN
Referral under Art.	• 14/07/2010	Nisamox Lactating Cow
33(4) of Directive		Amoxicillin, clavulanic acid, prednisolone
2001/82/EC		• Amoxiciiiii, ciavulanic aciu, preunisolone
Referral under Art.	• 14/07/2010	Combisyn Lactating Cow
33(4) of Directive		
2001/82/EC		Amoxicillin, clavulanic acid, prednisolone
Referral under Art. 34	• 14/07/2010	Doxycycline 50% WSP and associated names
of Directive		
2001/82/EC		Doxycycline hyclate
Referral under Art. 34	• 14/07/2010	Doxyfar 50% WSP and associated names
of Directive		
2001/82/EC		Doxycycline hyclate
Procedure under Art.	• 13/07/2010	Flexicam 1.5 mg/ml Suspension for Dogs
45 of Regulation (EC)	• 14/07/2010	Malautana
No 726/2004		Meloxicam
Procedure under Art.	• 14/09/2010	Acticam 1.5 mg/ml Oral Suspension for Dogs
45 of Regulation (EC)	• 15/09/2010	
No 726/2004		Meloxicam
Referral under Art. 34	• 09/11/2010	Baytril 10% oral solution and associated
of Directive		names
2001/82/EC		
		Enrofloxacin

# Guidelines and working documents in 2010

### **CVMP Efficacy**

Reference number	Document title	Status
EMA/CVMP/EWP/62867/2009	Concept Paper on proposed revision to the guideline for the conduct of efficacy studies for NSAIDs	Adopted for consultation, May 2010 (End of consultation 31 August 2010)
EMA/CVMP/330382/2007-Rev.2	Guideline on the conduct of bioequivalence studies for veterinary medicinal products	Adopted for 2 <sup>nd</sup> consultation, July 2010 (End of consultation 31 October 2010
EMA/CVMP/EWP/459868/2008- CONSULTATION	Guideline on demonstration of target animal safety and efficacy of veterinary medicinal products intended for use in farmed finfish	Consultation period extended, July 2010 (End of consultation 31 October 2010)

EMA/CVMP/EWP/81976/2010	Guideline on statistical principles for veterinary clinical trials	Adopted for consultation, September 2010 (End of consultation 31 March 2011)
EMA/CVMP/EWP/87114/2010	Concept paper for the revision of the guideline on the Conduct of efficacy studies for intramammary products for use in cattle	Adopted for consultation, September 2010  (End of consultation 31 December 2010)
EMA/CVMP/EWP/62867/2009	Concept paper for the revision to the Guideline for the conduct of efficacy studies for NSAIDs	Adopted for consultation, May 2010  (End of consultation extended until 30 November 2010)
EMA/CVMP/EWP/81987/2010	Concept paper for a guideline on the demonstration of palatability of veterinary medicinal products	Adopted for consultation, November 2010  (End of consultation extended until 28 February 2011)
EMA/CVMP/EWP/459883/2009	Guideline on veterinary medicinal products controlling <i>Varroa destructor parasitosis</i> in bees	Adopted, November 2010

#### **CVMP Environmental Risk Assessment (ERA)**

Reference number	Document title	Status
EMA/CVMP/ERA/430327/2009- CONSULTATION	Guideline on degradation of veterinary medicinal products in manure	Adopted for consultation, February 2010 (End of consultation, 31 August 2010)
EMA/CVMP/ERAWP/389867/2010	Concept paper on assessment of persistent, bioaccumulative and toxic (PBT) or very persistent and very bioaccumulative (vPvB) substances in veterinary medicine	Adopted for consultation, July 2010  (End of consultation 1 September 2010
EMEA/CVMP/ERA/172074/2008- Rev.2	Questions and Answers (Q&A) document on the implementation of CVMP guideline on Environmental Impact Assessment for veterinary medicinal products in support of the VICH guidelines GL6 (PHASE I) and GL38 (PHASE II)	Adopted, July 2010

#### **CVMP Immunologicals**

Reference number	Document title	Status
EMA/CVMP/IWP/58879/2010	Reflection paper on data requirements	Adopted, February 2010

Reference number	Document title	Status
	for swine influenza vaccines against pandemic (H1N1) 2009 influenza	
EMA/CVMP/IWP/105506/2007	Guideline on data requirements for multi-strain dossiers for inactivated vaccines against avian influenza (AI), Bluetongue (BT) and Foot-and-Mouth disease (FMD)	Adopted, March 2010
EMA/CVMP/IWP/43283/2010	Recommendation on the submission of multi-strain dossier applications for vaccines against avian influenza (AI), Bluetongue (BT) and Foot-and-Mouth disease (FMD)	Adopted, March 2010
EMA/CVMP/IWP/250147/2008	Guideline on data requirements to support in-use stability claims for veterinary vaccines	Adopted, March 2010
EMA/CVMP/IWP/582970/2009	Reflection paper on control of the active substance in the finished product for immunological veterinary medicinal products (IVMPs)	Adopted, March 2010
EMA/CVMP/IWP/439467/2007	Reflection paper on the demonstration of a possible impact of maternally derived antibodies on vaccine efficacy in young animals	Adopted, March 2010
EMA/CVMP/IWP/123243/2006- Rev.2	Guideline on data requirements for immunological veterinary medicinal products intended for Minor Use or Minor Species/ Limited markets	Adopted, April 2010
EMA/CVMP/IWP/596708/2010	Public statement on the number of tests required to control for complete inactivation in inactivated vaccines	Adopted, November 2010

## **CVMP Pharmacovigilance**

Reference number	Document title	Status
EMA/CVMP/PhVWP/729768/2009	Veterinary Pharmacovigilance 2009 Public Bulletin	Adopted, February 2010
EMA/CVMP/PhVWP/471721/2006	Recommendation for the basic surveillance of Eudravigilance Veterinary data	Adopted for consultation, May 2010 (End of consultation, 30 November 2010)
EMA/CVMP/10418/2009-Rev.2	CVMP combined VeDDRA list of clinical terms for reporting suspected adverse reactions in animals and humans to veterinary medicinal products	Adopted, July 2010
EMA/CVMP/553/03-Rev.5	List of species and breeds for electronic reporting of suspected adverse reactions in veterinary pharmacovigilance	Adopted, July 2010

EMA/CVMP/PhVWP/288284/2007-	Guidance notes on the use of VeDDRA	Adopted, July 2010
Rev.3	terminology for reporting suspected	
	adverse reactions in animals and	
	humans	
EMA/123352/2004-Rev.5	Revised call for comments on standard lists for EudraVigilance Veterinary	Adopted, July 2010
EMA/CVMP/VICH/647/2001	VICH GL30: Guideline on controlled list of terms	Adopted, September 2010
EMA/CVMP/VICH/123940/2006	VICH GL35: Guideline on pharmacovigilance of veterinary medicinal products: electronic standards for transfer of data	Adopted, September 2010 (End of consultation, 15 March 2011)
EMA/CVMP/VICH/355996/2005	VICH GL42: Data elements for submission of adverse event reports	Adopted, September 2010

## Joint CHMP/CVMP Quality

Reference number	Document title	Status
EMA/CHMP/CVMP/QWP/809114/ 2009	Concept paper on the revision of the guideline on process validation	Adopted for consultation, January 2010 (End of consultation, April 2010)
EMA/63033/2010	Concept Paper on the need for revision of the guideline on stability testing for applications for variations to a marketing authorisation	Adopted for consultation, February 2010 (End of consultation, 30 April 2010)
EMEA/CHMP/CVMP/QWP/80386/ 2010	Questions and Answers concerning stability issues of pharmaceutical bulk products used in the manufacture of drug products	Adopted, February 2010
EMA/CVMP/VICH/502/1999-Rev.1	VICH GL 18 residual solvents in new veterinary medicinal products, active substances and excipients	Adopted for consultation, May 2010 (End of consultation 31 October 2010)
EMA/CVMP/VICH/581467/2007	VICH GL 45 quality: bracketing and matrixing designs for stability testing of new veterinary drug substances and medicinal products	Adopted, May 2010
EMA/CHMP/CVMP/QWP/300039/ 2010	Question and Answer document on GMP compliance documentation that should be submitted in case of sterilisation of an active substance	Adopted, June 2010
EMA/CHMP/CVMP/QWP/199250/ 2009	Guideline on setting specifications for related impurities in antibiotics	Adopted for consultation, July 2010 (End of consultation 31 January 2011)
EMA/CVMP/QWP/565528/2010	Question and Answer document on the microbiological quality of	Adopted, October 2010

Reference number	Document title	Status
	veterinary premixes containing excipients of natural origin	
EMA/CVMP/QWP/565529/2010	Question and Answer document on	Adopted, October 2010
EMA/CVMP/QWP/574579/2010	Question and Answer document on veterinary powders for use in	Adopted, October 2010
EMA/CVMP/QWP/565531/2010	drinking water  Question and Answer document which clarifies the regulatory issues concerning whether or not it is permitted to authorise a multi-dose (parenteral) veterinary medicinal product for use both as an intramuscular injection and also an intramammary preparation	Adopted, October 2010
EMA/CHMP/CVMP/QWP/586330/2010	Question and Answers document on post-approval change management protocols	Adopted, October 2010
EMA/CHMP/CVMP/QWP/586385/2010	Question and Answer document on Variation B.II.b.4 (change of batch size of the finished product)	Adopted, October 2010

#### **CVMP Safety**

Reference number	Document title	Status
EMA/CVMP/SWP/543/03-Rev.1	Guideline on user safety for pharmaceutical veterinary medicinal products	Adopted, March 2010
EMA/CVMP/516817/2009	Guideline on data to be provided in support of a request to include a substance in the list of substances considered as not falling within the scope of Regulation (EC) No 470/2009	Adopted, November 2010

## **CVMP Scientific Advisory Group on Antimicrobials**

Reference number	Document title	Status
EMA/CVMP/SAGAM/736964/2009	Reflection paper on meticillin- resistant <i>Staphylococcus</i> pseudintermedius	Adopted for consultation, September 2010  (End of consultation 30 November 2010)
EMEA/CVMP/SAGAM/741087/2009	Reflection paper on the use of macrolides, lincosamides and streptogramins (MLS) in foodproducing animals in the European	Adopted for consultation, November 2010 (End of consultation 28

Union: development of resistance	February 2011)
and impact on human and animal	
health	

#### General

Reference number	Document title	Status
SOP/EMA/85634/2006-Rev.1	Standard Operating Procedure (SOP) on Evaluation procedure for applications and requests for the establishment of Maximum Residue Limits (MRLs) under Articles 3, 9, 10 and 15 of Regulation (EC) 470/2009	Adopted, February 2010
EMA/CVMP/38660/2010	Analysis of the functioning of the current veterinary legislation and proposals for its evolution to provide clarification on its views and additional areas for consideration by the European Commission	Adopted, July 2010